Taken together, our results show that the expression of oncogenic KRAS contributes to the activation of the alt-EJ pathway only at a post-transcriptional level in pancreatic cancer cells, which points to the need for a broader investigation of the role of factors and processes occurring between transcription and translation in these malignancies. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.